venetoclax
Minimal Residual Disease-Guided Imbruvica-Venclexta Beats Rituxan-Chemo as First-Line CLL Therapy
Premium
Based on data from the FLAIR study, researchers said that MRD-informed Imbruvica-Venclexta should be the new standard of care in this setting.
Tibsovo added to a standard two-drug treatment regimen extended event-free survival and reduced treatment failure in patients with IDH1-mutant acute myeloid leukemia.
Large Study Identifies Potential Therapeutic Targets for MDS Patients who Fail Initial Treatment
Premium
The study showed that the stem cell profiles of MDS patients could be used to stratify them into two subgroups associated with differential response to Venclexta.
Tibsovo, Azacitidine Combo Shows Improved Survival, Response in Newly Diagnosed IDH1-Mutant AML
Researchers at the ASH annual meeting suggested that Tibsovo-azacitidine could be a better option than Venclexta-azacitidine for chemo ineligible IDH1-mutant AML patients.
Researchers presented data exploring CLL patients' outcomes on fixed-duration combination regimens and on using uMRD to decide which patients can stop treatment.